Expert Review of Pharmacoeconomics & Outcomes Research最新文献

{"title":"Correction.","authors":"","doi":"10.1080/14737167.2026.2744040","DOIUrl":"https://doi.org/10.1080/14737167.2026.2744040","url":null,"abstract":"","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for prevention of RSV in adults: a cost-effectiveness analysis for Singapore.","authors":"Karan Thakkar, Ali Shajarizadeh, Nishu Gaind, Luka Ivkovic, Gopika Balasubramanian, Rengina Kefalogianni, Jessie Zhang, Kay Choong See, Andrea Lay-Hoon Kwa, Diana Mendes","doi":"10.1080/14737167.2026.2737558","DOIUrl":"10.1080/14737167.2026.2737558","url":null,"abstract":"<p><strong>Background: </strong>Respiratory syncytial virus (RSV) is a common virus causing severe illness in adults. RSV prefusion F protein subunit (RSVpreF) vaccine was approved by the Singapore Health Sciences Authority for adults aged 18-59 years at increased risk and for adults aged ≥ 60 years, to prevent RSV-associated lower respiratory tract disease. This study estimated the clinical and economic impact of RSVpreF vaccination for the prevention of RSV among adults in Singapore.</p><p><strong>Research design and methods: </strong>A Markov model projected clinical and economic outcomes of RSV for the vaccination of adults with RSVpreF compared to no intervention. Analyses were conducted from the healthcare system perspective, with direct costs (2025 Singapore dollars [S$]) and outcomes discounted at 3% annually; scenario/sensitivity analyses tested model robustness.</p><p><strong>Results: </strong>Compared to no intervention, RSVpreF vaccination would prevent 4,675 hospitalizations, 14,064 emergency department cases, and 37,631 outpatient visits over lifetime, averting S$31.92 million in direct medical costs with a gain of 2,675 quality-adjusted life years (QALYs). The RSVpreF vaccine would be cost-effective up to S$440.79/dose under a threshold of 1 × gross domestic product per capita per QALY gained (S$122,370).</p><p><strong>Conclusions: </strong>RSVpreF vaccination would substantially reduce the clinical and economic burden of RSV among adults in Singapore.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in economic evaluation: enhancing cost-effectiveness frameworks in precision pain treatment.","authors":"Fredrick Zmudzki, Mickaël Hiligsmann, Jan S Groenewegen, Rob J E M Smeets","doi":"10.1080/14737167.2026.2738030","DOIUrl":"10.1080/14737167.2026.2738030","url":null,"abstract":"","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An application of random forest regression for predicting healthcare costs using administrative databases.","authors":"Isabella Sala, Sara Conti, Ippazio C Antonazzo, Lorenzo Losa, Pietro Ferrara, Davide Rozza, Carla Fornari, Giacomo Crotti, Giuseppe Sampietro, Alberto Zucchi, Vincenzo Bagnardi, Lorenzo G Mantovani","doi":"10.1080/14737167.2026.2738028","DOIUrl":"10.1080/14737167.2026.2738028","url":null,"abstract":"<p><strong>Background: </strong>Accurate healthcare cost predictions are essential for health economic decision-making. We propose a bottom-up approach that aggregates individual-level predictions to estimate expenditures for specific population segments without relying on <i>a priori</i> segmentation.</p><p><strong>Methods: </strong>This retrospective population-based study used administrative healthcare data (2011-2023) from the Health Protection Agency of Bergamo (Italy). We traced 5-year healthcare resource utilization to predict individual's healthcare costs in the following year using random forest regression algorithms. Individual predictions were aggregated to derive mean per-capita cost estimates for the overall population and selected high-impact subgroups. Performance was assessed at the individual-level using error metrics, and at the population-level using prediction error (PE).</p><p><strong>Results: </strong>At the individual-level, algorithms had a poor performance, systematically underestimating high-cost users. However, aggregated predictions were reliable. For the overall population, pre-pandemic PEs ranged from -2.5% to -0.4% and stabilized by 2023 (PE = -0.7%), after 2020-2021 volatility. In high-impact groups, dialysis and diabetic patients showed consistent PE temporal trends not exceeding -10%. Other segments exhibited more marked underestimations, with PE reaching -30%.</p><p><strong>Conclusion: </strong>Machine learning-based bottom-up approach applied to administrative databases demonstrated potential for population-level public healthcare expenditure forecasting within the geographical context of this study. These findings support further evaluation of this approach for budget planning and health economic applications, while external validation across different areas and administrative settings will be necessary to assess its generalizability.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness and value implications of veligrotug versus teprotumumab for moderate-to-severe thyroid eye disease in the United States.","authors":"Zhengxuan Li, Christina Y Weng, Hua Chen, Moosa Tatar","doi":"10.1080/14737167.2026.2737568","DOIUrl":"10.1080/14737167.2026.2737568","url":null,"abstract":"<p><strong>Background: </strong>Thyroid eye disease (TED) is a debilitating autoimmune condition. Teprotumumab is effective but costly, whereas veligrotug is a recently approved IGF-1R inhibitor requiring fewer infusions.</p><p><strong>Research design and methods: </strong>A 1-year decision-analytic model compared veligrotug with teprotumumab from a US payer perspective. Clinical inputs came from pivotal phase 3 trials, and costs included drug, infusion, and monitoring. One-way (treatment cost, adherence), two-way, and probabilistic sensitivity analyses used willingness-to-pay (WTP) thresholds of USD 150,000 and 500,000 per quality-adjusted life-year (QALY).</p><p><strong>Results: </strong>At a WAC of USD 450,000 per course, veligrotug's fully loaded cost was USD 459,850 versus USD 444,949 for teprotumumab in a 75-kg patient. Veligrotug was slightly more costly and no more effective (0.0149 vs 0.0161 QALYs), with a negative incremental net monetary benefit of USD 15,080 at USD 150,000/QALY. It was cost-effective in 19.2% of probabilistic iterations and became cost-effective only when fully loaded cost fell below approximately USD 444,800, corresponding to a WAC about 3.4% below launch price.</p><p><strong>Conclusions: </strong>At current price and efficacy, veligrotug is not economically dominant over teprotumumab. A modest price reduction could achieve cost-effectiveness, while its shorter infusion course may add real-world value.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in mortality attributable to complications of medical and surgical care among cancer patients.","authors":"Shangcheng Yan, Zhen Cao, Qiyao Zhang, Bingrong Chen, Bohan Huang, Ziwen Liu","doi":"10.1080/14737167.2026.2737523","DOIUrl":"https://doi.org/10.1080/14737167.2026.2737523","url":null,"abstract":"<p><strong>Background: </strong>Complications of medical and surgical care (CMSC) are unintentional harms from medical interventions. Their mortality burden among cancer patients remains understudied. We examined trends and disparities in CMSC-attributable mortality among U.S. cancer patients over two decades, including the COVID-19 pandemic.</p><p><strong>Research design and methods: </strong>Retrospective cohort study was conducted using the SEER database for cancer patients who died of CMSC in 2003-2022. We calculated age-adjusted incidence-based mortality rates. Joinpoint regression estimated annual percent changes (APCs) across pre-pandemic (2003-2019), pandemic (2019-2021), and post-pandemic (2021-2022) periods.</p><p><strong>Results: </strong>Overall mortality rate was 1.85 per million person-years (3,219 deaths). Mortality increased in 2003-2017 (APC 7.68%; 95% CI, 4.76% to 11.56%), then declined through 2019 (APC -4.81%; 95% CI, -7.86% to -1.59%). This progress reversed during pandemic (APC 6.41%; 95% CI, 3.61% to 9.40%), followed by a post-pandemic downturn (APC -34.31%). Higher mortality, faster pre-pandemic increases, or slower recoveries occurred among elderly, males, Black individuals, lower-income and nonmetropolitan residents, and localized cancer patients.</p><p><strong>Conclusions: </strong>CMSC remains an important death cause for cancer patients. Strengthening safety practices and healthcare system resilience is essential to sustain progress and improve equity in patient safety. Limitations include short post-pandemic period and unmeasured confounders.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory and clinical trial exclusion of pregnant women: economic implications for preventive interventions in low-income countries.","authors":"Malvina Hoxha, Elira Tashi, Brunilda Elezi, Hedie Haxhiu","doi":"10.1080/14737167.2026.2737547","DOIUrl":"10.1080/14737167.2026.2737547","url":null,"abstract":"<p><strong>Introduction: </strong>Preventive interventions during pregnancy represent a high-return investment, and some of the most cost-effective strategies because they help prevent diseases, reducing the cost for hospital treatment, and neonatal intensive care treatments, complications, and long-term health problems for both mother and child. We searched PubMed, Google, ClinicalTrials.gov, the International Clinical Trials Registry Platform, and Ministry of Health websites from low-income countries (LICs) to identify clinical trials and regulatory documents governing pregnancy-related research.</p><p><strong>Areas covered: </strong>Limited research capacity in LICs restrict the generation of robust clinical evidence for preventive interventions during pregnancy. Consequently, pregnant women may receive routine care based on limited evidence, while uncertainty remains regarding treatment effectiveness, safety, and economic value. This evidence gap may compromise the reliability of cost-effectiveness and cost-benefit analyses by relying on incomplete or non-contextualized clinical and economic data.</p><p><strong>Expert opinion: </strong>Strengthening maternal health research requires responsible inclusion of pregnant women in clinical trials, integration of health economic evaluation into research designs, regulatory harmonization, and sustainable data systems. Improving the quality of clinical and economic evidence is essential to support efficient resource allocation, reduce maternal and neonatal health disparities, and ensure that preventive interventions achieve their full public health and economic potential.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obstetric pharmacoeconomics.","authors":"Ahizechukwu C Eke, Emeka P Igbodike","doi":"10.1080/14737167.2026.2738026","DOIUrl":"10.1080/14737167.2026.2738026","url":null,"abstract":"<p><strong>Introduction: </strong>Pharmacoeconomic principles are increasingly shaping modern obstetric pharmacology as maternal therapeutics become more complex, costly, and precision-driven. Rising rates of hypertensive disorders of pregnancy, gestational diabetes, obesity, maternal cardiovascular disease, and medically complicated pregnancies have intensified the need for cost-effective therapeutic strategies that optimize maternal and neonatal outcomes while minimizing unnecessary healthcare expenditure.</p><p><strong>Areas covered: </strong>This review examines contemporary pharmacoeconomic concepts in obstetric pharmacology, including cost-effectiveness analysis, quality-adjusted life years, implementation science, and value-based maternal therapeutics. Major domains reviewed include antihypertensive therapy, aspirin prophylaxis, diabetes pharmacotherapy, antiretroviral therapy in pregnancy, anticoagulation, perinatal mental health, lactation, fetal therapeutics, pharmacogenomics, precision dosing, digital health integration, and emerging artificial intelligence applications in maternal fetal medicine. The review further explores linked maternal-child outcome modeling, implementation-sensitive economic evaluation, and the growing role of pharmacometrics and biomarker-guided therapeutics in precision pregnancy care. The review also proposes a life-course framework linking pregnancy therapeutics to inter-generational health, implementation outcomes, and sustainable maternal healthcare systems globally.</p><p><strong>Expert opinion: </strong>Obstetric pharmacology is entering a precision-medicine era where therapeutic value will depend on biologic profiling, implementation feasibility, and long-term maternal-child outcomes. Future pharmacoeconomic frameworks should integrate precision therapeutics, biomarker-guided strategies, real-world effectiveness, and lifelong maternal cardiovascular risk reduction.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-16"},"PeriodicalIF":2.2,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China.","authors":"Weiqi Chen, Yongyi Wu, Qiyun Zhu, Bin Jiang, Lei Si, Zhao Yang","doi":"10.1080/14737167.2026.2718414","DOIUrl":"10.1080/14737167.2026.2718414","url":null,"abstract":"<p><strong>Background: </strong>Zanubrutinib has demonstrated superior efficacy and safety over ibrutinib for Waldenström macroglobulinemia (WM) in the phase 3 ASPEN trial, but its cost-effectiveness in China remains unknown. This study evaluated the cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for WM from the Chinese healthcare system perspective.</p><p><strong>Methods: </strong>A three-state partitioned survival model (progression-free, progressive disease, death) was developed over a 15-year horizon using ASPEN trial data. Survival was extrapolated using parametric models and adjusted by relative survival. Direct medical costs were sourced from Chinese databases. ICERs were calculated using a willingness-to-pay threshold of $37,849/QALY (three times China's 2023 GDP per capita). Deterministic and probabilistic sensitivity analyses were conducted.</p><p><strong>Results: </strong>Zanubrutinib resulted in an incremental gain of 0.084 QALYs at a cost saving of $26,768 per patient compared with ibrutinib, yielding an ICER of -$318,719/QALY. The negative ICER indicates that zanubrutinib is both more effective and cost-saving (i.e. a dominant strategy) relative to ibrutinib. Deterministic and probabilistic sensitivity analyses confirmed the robustness of these findings.</p><p><strong>Conclusion: </strong>Under current Chinese pricing and healthcare system conditions, zanubrutinib is a cost-effective and dominant alternative to ibrutinib for first-line treatment of WM.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and public perspectives on artificial intelligence in healthcare and health research: comfort, perceived utility, and concern.","authors":"Nicolas Hall, Bill Byrom, Thomas Smith, Jessica James, Lina Eliasson","doi":"10.1080/14737167.2026.2717295","DOIUrl":"10.1080/14737167.2026.2717295","url":null,"abstract":"<p><strong>Background: </strong>Public perceptions of artificial intelligence (AI) in healthcare have been found to be generally favorable if specific areas of concern are addressed. This exploratory survey aimed to elicit levels of comfort, perceived utility, and concern among people with and without chronic health conditions across a range of healthcare, health training, and health research scenarios.</p><p><strong>Research design and methods: </strong>A cross-sectional survey was conducted with adults based in the United Kingdom. Quantitative data were presented using descriptive statistics, and non-parametric tests were used to detect differences between scenarios and the influence of sociodemographic characteristics. Free-text responses were analyzed using thematic analysis.</p><p><strong>Results: </strong>Study participants had a mean age of 49.04 years (range 19-92) and were predominantly male (57.14%). The sample contained people with (49.07%) and without (50.93%) chronic health conditions. Most participants reported they were comfortable in each scenario (56.5-71.4%), found AI to be useful (60.2-73.3%), and indicated they were only slightly or not at all concerned (59.6-70.2%).</p><p><strong>Conclusions: </strong>This study found that AI is broadly acceptable to the public across a variety of different healthcare and health research scenarios. Future research should build on these exploratory findings to interrogate the acceptability of AI across different contexts and over time.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}